CoChat
Sign Up
Cited by 94Diabetes Management and ResearchDiabetes Treatment and ManagementDiabetes Management and Education

The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes

Rodbard, Helena W., Peters, Anne L., Slee, April, Cao, Anjun, Traina, Shana B., Alba, Maria·2017·Diabetes Care
DOI 10.2337/dc16-1353
Open this paper in CoChat — free account

Abstract

Objective To assess the effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic parameters and measures of glucose variability assessed by a 9-point self-monitoring blood glucose (SMBG) and continuous glucose monitoring (CGM) profiles, and patient-reported outcomes as an add-on to insulin among participants with type 1 diabetes. Research design and methods In this randomized, double-blind study, 351 participants received canagliflozin 100 or 300 mg or placebo for 18 weeks. Change from baseline in daily mean glucose and SD was measured using a 9-point SMBG profile. In a subset of 89 participants who underwent CGM, the change from baseline in mean glucose, measures of glycemic variability (SD, coefficient of variation, and mean amplitude of glycemic excursions), and time spent in glycemic ranges were assessed. Change in treatment satisfaction was evaluated using the Diabetes Treatment Satisfaction Questionnaire (n = 328). Results At week 18, reductions in daily mean glucose and SD measured using the 9-point SMBG profile were seen with canagliflozin 100 and 300 mg versus placebo. Reductions in mean glucose (-1.2, -0.7, and 0.6 mmol/L) and measures of glycemic variability assessed by CGM, such as changes in glucose SD (-0.3, -0.7, and 0.1 mmol/L), were also seen with canagliflozin 100 and 300 mg versus placebo, respectively. Canagliflozin 100 and 300 mg were associated with increases in time spent within target (glucose >3.9 to ≤10.0 mmol/L) compared wit…

Integrity signals

Registry

Crossref · 10.2337/dc16-1353

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Use of preventative processes may have contributed to the lower rates of ketoacidosis seen in some studies of SGLT inhibitors for adjunctive glycemic management in type 1 diabetes compared with those that did not include preventative strategies.

    “Use of these processes may have contributed to the lower rates of ketoacidosis seen in some of the studies of these agents for adjunctive glycemic management in people with type 1 diabetes (314-316) compared with those that did not include preventative strategies (310,317).”

    From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [317]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rodbard, H. W., Peters, A. L., Slee, A., Cao, A., Traina, S. B., & Alba, M.
Affiliations
  • Endocrine and Metabolic Consultants, Rockville, MD
  • University of Southern California (US)
  • Axio Research, Seattle, WA
  • Janssen Research & Development (United States) (US)
  • Janssen (United States) (US)
Corresponding author
Rodbard, Helena W.
ORCID
Venue
Diabetes Care
Publisher
American Diabetes Association
Published
2016-11-29
Volume
40
Issue
2
Pages
171-180
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
DOI
10.2337/dc16-1353
OpenAlex
W2559579283
Cited by
94
References
5
Citations by year
2026: 3 · 2025: 6 · 2024: 4 · 2023: 6 · 2022: 7 · 2021: 10 · 2020: 17 · 2019: 16 · 2018: 17 · 2017: 8
FWCI
13.72
Type
journal article
Language
en
Open access
closed
Licence
www.diabetesjournals.org/content/license (vor, 52 d)
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Funders
Janssen Research & Development, LLC
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords
canagliflozin, SGLT2 inhibitors, type 1 diabetes, glycemic variability, continuous glucose monitoring, self-monitoring of blood glucose, time in range, mean blood glucose, insulin dose reduction, treatment satisfaction, patient-reported outcomes, body weight, hyperglycemia, hypoglycemia
MeSH terms
Canagliflozin, Patient Reported Outcome Measures, Sodium-Glucose Transporter 2 Inhibitors, Adult, Aged, Diabetes Mellitus, Type 1, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Blood Glucose Self-Monitoring, Logistic Models, Endpoint Determination, Sodium-Glucose Transporter 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review